

1 **Real-World Genetic Characteristics of Candidates for Implantable Cardioverter-Defibrillators**  
2 **with Dilated Cardiomyopathy**

3 <sup>1,\*</sup>In-Soo Kim, <sup>2,\*</sup>Yoonjung Kim, <sup>1</sup>Jiwon Seo, <sup>3</sup>Hyemoon Chung, <sup>4</sup>Jung-Woo Son, <sup>5</sup>Sang Jin Ha,  
4 <sup>6</sup>Jaemin Shim, <sup>1</sup>Jong-Youn Kim, <sup>1</sup>Se-Joong Rim, <sup>2,€</sup>Kyung-A Lee, <sup>1,€</sup>Eui-Young Choi

5

6 <sup>1</sup>Division of Cardiology, Heart Center, Gangnam Severance Hospital; <sup>2</sup>Department of Laboratory  
7 Medicine, Gangnam Severance Hospital; <sup>3</sup>Division of Cardiology, Kyung Hee University Hospital;  
8 <sup>4</sup>Division of Cardiology, Wonju Severance Christian Hospital, <sup>5</sup>Department of Internal Medicine-  
9 Cardiology, Gangneung Asan Hospital, <sup>6</sup>Division of Cardiology, Korea University Anam Hospital,  
10 Seoul, Republic of Korea

11

12 \*Both authors equally contributed to this work.

13 **Short title:** Genetics in ICD candidates of DCM

14

15 **€Corresponding authors:**

16 **Eui-Young Choi, MD, PhD**

17 Professor of Internal Medicine

18 Division of Cardiology, Heart Center, Gangnam Severance Hospital

19 Yonsei University College of Medicine

20 211 Eonju-Ro, Gangnam-Gu

21 Seoul 06273, Republic of Korea

22 Tel: +82-2-2019-3310, FAX: +82-2-3463-3882

23 Email: choi0928@yuhs.ac

24 **Kyung-A Lee, MD, PhD**

25 Professor of Laboratory Medicine

26 Gangnam Severance Hospital, Yonsei University College of Medicine

27 211 Eonju-Ro, Gangnam-Gu, Seoul 06273, Republic of Korea

28 Tel: +82-2-2019-3531, FAX: +82-2-2019-4822

29 Email: KAL1119@yuhs.ac

1 **Total word count:** 6,101

2 **Abstract**

3 **Background:** The real-world prevalence of sudden cardiac death (SCD)–related gene mutations and  
4 their relationship with implantable cardioverter-defibrillator (ICD) implantation in dilated  
5 cardiomyopathy (DCM) has not been clearly investigated.

6 **Methods:** This study included patients with sporadic DCM with persistent left ventricular ejection  
7 fraction (LVEF)  $\leq 35\%$  even after 3 months of guideline-directed medical treatment or those with an  
8 ICD for secondary prevention and LVEF  $< 50\%$ . Genetic tests targeting 444 pan-cardiomyopathy  
9 genes (including 36 core DCM genes) were performed, along with the collection of clinical and  
10 electrophysiological information.

11 **Results:** A total of 105 patients were enrolled (median age, 65.0 [57.5–75.0] years), and 33 (31%)  
12 were women. The average LVEF was  $27.4 \pm 5.9\%$ , and 46 patients (44%) had ICD or cardiac  
13 resynchronization therapy with ICD (34 for primary prevention and 12 for secondary prevention  
14 purpose) at the time of enrollment. Fourteen patients (13%) had pathogenic (P) or likely pathogenic  
15 (LP) variants (comprising 6 *TTN*, 4 *DSP*, 2 *TNNT2*, 1 *RBM20*, 1 *DSG* and 1 *MYBPC3*, one patients  
16 had both *DSP* and *RBM20*), and 59 patients (56%) had P/LP/variant of uncertain significance (VUS)  
17 in the 36 core DCM genes. Twenty-eight patients (27%) harbored SCD-related gene variants (14 *DSP*,  
18 11 *FLNC*, 9 *RBM20* and 2 *TMEM43*). The prevalence of SCD gene variants tended to be higher in the  
19 secondary prevention and non-ICD groups (33.3% for secondary purposes, 11.8% for primary  
20 purposes, and 33.8% for non-ICD;  $p = 0.058$ ).

21 **Conclusions:** In patients with advanced heart failure and DCM, P/LP-validated DCM variants were  
22 not common in sporadic cases. However, when extended to VUS, approximately half of the patients  
23 had core DCM-related variants. The prevalence of SCD variants was not lower in the non-ICD group,  
24 thus suggesting a potential risk of fatal arrhythmia.

25 (Trial registration: CRIS KCT0004913)

26 **Keywords:** dilated cardiomyopathy, genetics, heart failure, sudden cardiac death

27

28

29 **Nonstandard Abbreviations and Acronyms**

- 1 DCM: dilated cardiomyopathy
- 2 GDMT: guideline-directed medical treatment
- 3 SCD: sudden cardiac death
- 4 NYHA: New York Heart Association
- 5 CRT: cardiac resynchronization therapy
- 6 P: pathogenic
- 7 LP: likely pathogenic
- 8 MAF: minor allele frequency
- 9 CRTD: CRT with defibrillator
- 10 BBB: bundle branch block
- 11 VUS: variant of uncertain significance
- 12 ARVC: arrhythmogenic right ventricular cardiomyopathy
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26

## 1 **Introduction**

2 Dilated cardiomyopathy (DCM) is a disease that accounts for approximately 30% of total heart failure  
3 (HF) cases with reduced ejection fraction and is a serious disease with a mortality rate of 20%–30%  
4 within 5 years.<sup>1</sup> However, the exact cause of nonischemic DCM is not well identified, and evidence  
5 for genetic contribution is continuously increasing.<sup>2</sup> Current treatment guidelines around the world  
6 state that implantable cardioverter-defibrillators (ICDs) should be inserted for primary prevention  
7 purposes in patients with symptomatic DCM with left ventricular ejection fraction (LVEF) < 35%,<sup>3</sup>  
8 but a recently published DANISH trial (researcher-led study) announced that the primary preventive  
9 effect of ICD is not different from that of maximum medical treatment in the state of strictly  
10 following the guideline-directed medical treatment (GDMT).<sup>4,5</sup> Complications such as device-related  
11 infection or inappropriate defibrillator shock are also issues faced by patients with ICD. After ICD  
12 implantation based on LVEF as a primary prevention measure, electrical shock never occurs in 90%  
13 of patients, and some patients may receive heart transplants or a left ventricular (LV) assist device  
14 (LVAD) within a few years after ICD implantation. However, in the extended follow-up study  
15 encompassing 9.6 years, ICD was benefited by a reduction in sudden cardiac death (SCD) in age ≤ 70  
16 years (5% vs. 11%), although events rate was far lower than other previous studies.<sup>5</sup> It suggests the  
17 importance of identifying individuals who are prone to developing early disease onset and progression  
18 to advanced HF (i.e., individual risk assessment). Genetic factors are important determinants of early  
19 onset and progression to HF in DCM. In addition, specific genetic mutations are known to be related  
20 to fatal arrhythmic events.<sup>3</sup> Therefore, recent cardiomyopathy guidelines emphasize the role of genetic  
21 mutations in risk stratification, particularly the risk of sudden arrhythmic death, and provide specific  
22 instructions for gene mutation-guided ICD implantation even if LVEF > 35%.<sup>3</sup> A recent large-scale  
23 multicenter study for advanced HF due to DCM showed that the presence of core genetic mutations  
24 was related to disease progression to heart transplantation (HT) or LVAD implantation.<sup>6</sup> However,  
25 currently, genetic mutation-guided prophylactic ICD implantation is not popular in real-world practice.  
26 Therefore, in this study, we sought to evaluate the prevalence of genetic mutations in ICD candidates  
27 for sporadic nonischemic DCM by using core gene and extended pan-cardiomyopathy panels. In real-  
28 world practice, we sought to investigate the prevalence of SCD gene mutations in real-world ICD  
29 candidates and whether it differed between ICD-implanted patients and nonimplanted patients blinded  
30 to genetic information.

31

32

1

## 2 **Method**

### 3 **Study population**

4 Study participants were prospectively enrolled after obtaining agreement for study participation in  
5 five tertiary university hospitals (Gangnam Severance Hospital, Wonju Severance Christian Hospital,  
6 Korea University Anam Hospital, Kyug Hee University Hospital and Gangneung Asan Hospital).  
7 The inclusion criteria for study enrollment were (1) patients who were diagnosed with nonischemic  
8 DCM with New York Heart Association (NYHA) functional class II or higher and continuously  
9 reduced LVEF of 35% or less than 35% even after 3 months of GDMT after diagnosis regardless of  
10 whether primary prevention ICD or cardiac resynchronization therapy (CRT) was performed or (2)  
11 patients with nonischemic DCM with LVEF < 50% for more than 3 months after ICD was  
12 administered for secondary prevention purposes. Patients with malignant tumors, cerebrovascular  
13 accidents, or neuromuscular diseases who were expected to survive within 6 months were excluded  
14 from the study. Blood samples for genetic testing were extracted by expert phlebotomists and then  
15 transferred to the central core laboratory (Gangnam Severance Hospital Genetic Laboratory) for  
16 further analysis. The study protocol was approved by Gangnam Severance and four other centers (IRB  
17 No 3-2019-0372, CR319168, 2020AN0454, KHUH2020-03-071 and GNAH2020-01-005), and the  
18 clinical data of the participants who agreed to participate in the study were extracted from medical  
19 records and entered into a database.

20

### 21 **Clinical data collection**

22 Data on age, sex, history of hypertension and diabetes, HF medication, NYHA functional class,  
23 glomerular filtration rate, blood sodium level, and hemoglobin level were collected and entered into a  
24 database. A family history of DCM or HF was also obtained. Echocardiographic data such as LV  
25 dimension, diastolic functional parameters, left atrial (LA) diameter and volume, and tricuspid  
26 regurgitant velocity were collected from echo reports from each center. For the electrocardiogram  
27 (ECG) data, presence of atrial fibrillation (AF), QRS duration, bundle branch block (BBB), LV  
28 hypertrophy, and number of fragmented QRS in the 12-lead ECG were obtained.

29

### 30 **DNA preparation**

31 Genomic DNA were extracted from ethylenediaminetetraacetic acid-treated whole blood samples via  
32 QIAamp DNA Blood Mini kit (Qiagen, Venlo, The Netherlands). Each DNA sample was checked for  
33 purity using a NanoDrop 1000 system (Thermo Fisher Scientific, Rockford, IL, USA), and DNA

1 concentration was determined using a Qubit 3.0 fluorometer (Thermo Fisher Scientific). Extracted  
2 DNA was stored at -80°C until further use.

### 3 **DCM Core 36 gene panel design** <sup>2,7-9</sup> (Figure 1)

4 To construct the core DCM gene panel, a literature search of the PubMed database was performed for  
5 targeted gene selection.<sup>9</sup>

### 6 **Pan-cardiomyopathy gene panel** <sup>2,7,8,10,11</sup> (Supplemental figure 1)

7 To construct the Pan-cardiomyopathy gene panel, a literature search of the PubMed database was  
8 performed for targeted gene selection. Subsequently, a comprehensive Pan-cardiomyopathy gene  
9 panel was curated, encompassing 444 genes associated with various cardiomyopathy phenotypes,  
10 such as Dilated Cardiomyopathy (DCM), Hypertrophic Cardiomyopathy (HCM), Arrhythmogenic  
11 Right Ventricular Cardiomyopathy (ARVC), as well as nuclear DNA genes (MT-nDNA) implicated in  
12 mitochondrial cardiomyopathy.

### 13 **Library construction and sequencing**

14 For NGS, a library was prepared using the customized Capture probes produced by Celemics, Inc.  
15 (Seoul, Korea) to cover coding sequence regions of target genes (Supplemental figure 1). The libraries  
16 were prepared using nucleic acid input according to the manufacturer's instructions. The constructed  
17 library was used for sequencing with the Illumina NextSeq 550Dx platform (Illumina, San Diego, CA,  
18 USA) with the 2 × 150 base pair paired-end reads.

### 19 **Bioinformatics Pipeline for NGS Gene Panel Analysis**

20 Quality control of the sequence reads (FASTQ paired-end reads) were initially performed  
21 using FASTQC <sup>12</sup>. Subsequently, Trimmomatic (version 0.39) <sup>13</sup> was employed to trim  
22 adapter sequences and eliminate low-quality sequences from the raw sequencing data. The  
23 processed reads were aligned to the reference genome (hs37d5) using BWA-MEM (version  
24 0.7.17) <sup>14</sup>. Picard tools (version 2.27.1) <sup>15</sup> were then used to mark duplicated reads and sort  
25 BAM files. Variant calling for SNVs and InDels was performed using The Genome Analysis  
26 Toolkit (GATK) HaplotypeCaller (version 4.2) <sup>16</sup>, with VarScan (version 2.4.4) <sup>17</sup> serving as  
27 complementary method. Bcftools (version 1.10.2) <sup>18</sup> was utilized for splitting multi-allelic  
28 sites and normalizing variants to produce left-aligned VCF format. Our in-house pipeline,  
29 which realigns reads to a target region masked reference genome, was employed to identify

1 variants potentially affected by homologous. ExomeDepth<sup>19</sup> was employed for identifying  
2 copy number variations.

3

#### 4 **Classification of P/LP variants and VUS**

5 To standardize variant interpretation, variants were classified as P, LP or uncertain significance based  
6 on American College of Medical Genetics and Genomics standards and guidelines. VCF files were  
7 annotated with ANNOVAR<sup>20</sup> and Variant Effect Predictor. Variants were further filtered with altered  
8 allele frequency > 30% and 30x coverage. The variant was classified based on refined American  
9 College of Medical Genetics and Genomics (ACMG) standards and specific guidelines for inherited  
10 cardiac conditions.<sup>21-24</sup> The impact of missense change was predicted with REVEL.<sup>25</sup> REVEL scores  
11 >0.644 are more likely to indicate pathogenic variants and scores <0.290 are more likely to indicate  
12 benign variants.<sup>26</sup> Public databases such as Human Gene Mutation Database professional version,  
13 release 2016.1, ClinVar, and Atlas of Cardiac Genetic Variation were used.

14

#### 15 **Statistical analysis**

16 The baseline characteristics of the patients are described as mean  $\pm$  standard deviation for parameters  
17 following normal distribution and median (interquartile range) for parameters without normal  
18 distribution. The normality of distribution was evaluated using the Shapiro–Wilk test or Kolmogorov–  
19 Smirnov test. Differences in clinical features, blood test findings, echocardiography, and  
20 electrophysiological findings among ICD implementation groups or genetic mutation groups were  
21 analyzed using Student’s t-test or analysis of variance with post hoc analysis. The Mann–Whitney U  
22 test and Kruskal–Wallis test were performed for nonparametric variables. Differences, such as the  
23 presence or absence of genetic mutations and dichotomous variables, were analyzed using the chi-  
24 square test. The analyses were performed using SPSS 27 (IBM Corp), and a two-sided p-value < 0.05  
25 was considered significant.

26

## 27 **Results**

### 28 **Baseline clinical characteristics**

29 The median age of the patients was 65.0 (57.5–75.0) years, and 33 patients (31%) were women. The  
30 average LVEF was  $27.4 \pm 5.9\%$ , and 46 patients (44%) had ICD or CRT with defibrillator (CRTD)  
31 (34 for primary prevention and 12 for secondary prevention purposes). Twenty-nine (28%) patients

1 had persistent AF, and 28 (27%) had BBBs (24 left BBBs and 4 right BBBs). The average LA  
2 anteroposterior dimension and E/e' were  $45.0 \pm 8.4$  mm and  $15.2 \pm 6.9$ , respectively. The baseline  
3 clinical characteristics of the patients are summarized in **Table 1**.

4

#### 5 **Genetic test results in targeted 36 core DCM genes and 444 pan-cardiomyopathy genes**

6 Fourteen (13%) patients had P or LP variants (six *TTN*, four *DSP*, two *TNNT2*, one *RBM20*, one  
7 *DSG2*, and one *MYBPC3*, one patient had both *DSP*, and *RBM20*), and 59 (56%) had P/LP/variant of  
8 uncertain significance (VUS) in the 36 core DCM panel. The three most common variants up to the  
9 VUS were *TTN*, *DSP* and *FLNC*. The variant coding proteins comprised 36% sarcomere; 20%  
10 desmosome; 18% cytoskeleton; 11% Z-disk; 8% ribonucleic acid binding; 3% junctional membrane  
11 and 4% ion channels, co-chaperones, or transcription factors (**Figure 2**). When extended to 444 pan-  
12 cardiomyopathy-associated gene panels, 34 (32%) patients had P/LP variants, and 102 (97%) had  
13 P/LP/VUS. The P/LP variants detected in the pan-cardiomyopathy panel comprised two *HFE*, two  
14 *ACADS*, one *HPS1*, one *GNE*, one *OPA1*, three *GAA*, two *STAR*, one *TREX1*, one *NEK8*, one *FKRP*,  
15 one *GLB1*, one *FANCI*, one *ANO5*, one *TMEM126A*, one *GNPTAB*, two *GNE*, one *ALMS1*, one  
16 *NUP107*, one *IFIH1*, and one *WFS1* variant.

17

#### 18 **Clinical, echocardiography, and electrophysiological findings according to genetic mutation**

19 When comparing patients with P/LP variants (in the 36 core and 444 pan-cardiomyopathy panels) and  
20 others for clinical, echocardiographic, and electrophysiological findings, patients with P/LP variants  
21 were younger, were predominantly females, and had reduced diastolic and systolic functions; however,  
22 statistical significance was not reached. When extended to VUS, patients with LP/P or VUS showed  
23 similar trends, but statistical significance was not reached (**Tables 1–3**). Patients with SCD-related  
24 variants according to the European Society of Cardiology cardiomyopathy guidelines were 28 (27%)  
25 up to VUS. They comprised 14 *DSP*, 11 *FLNC*, 9 *RBM20*, and 2 *TMEM43* variants (three patients had  
26 more than one SCD variant); however, no *LMNA* variants were detected in this population. The  
27 prevalence of SCD gene variants tended to be higher in the secondary prevention ICD group than in  
28 the primary prevention ICD group (33.3% for secondary purposes, 11.8% for primary purposes, and  
29 33.8% for no ICD;  $p = 0.058$ ) (**Figure 3**). An interesting finding was that the prevalence of SCD  
30 variants was not lower in the non-ICD group than in the secondary prevention ICD group, thus  
31 suggesting exposure to the risk of SCD. However, there were no significant differences in the  
32 prevalence of AF and BBB between the SCD variant groups and the other groups. Interestingly, the



1 prevalence of ICD/CRTD implantation was lower in patients with SCD variants (30% in the SCD  
2 variants group and 49% in the other groups,  $p = 0.162$ ) (**Table 4**). The reason for non-ICD  
3 implantation was the patient denial or doctors' decision to wait, thus suggesting that it was not based  
4 on scientific background. When comparing the sarcomere gene mutation-positive group ( $n = 29$ , 28%)  
5 with the other groups, no significant differences were observed in the echocardiography and clinical  
6 characteristics (**Table 5**).

7

## 8 **Discussion**

9 We found that the prevalence of P/LP variants was not as high as 14% in the 36-core DCM panel and  
10 32% in the 444 pan-cardiomyopathy panels in ICD candidates with sporadic DCM. However, when  
11 extended to VUS, the prevalence of genetic mutations significantly increased to 56% in the core DCM  
12 panel and 97% in the pan-cardiomyopathy panel, thus suggesting a potential genetic background.  
13 Patients tended to be younger, were predominantly female, and had poorer systolic and diastolic  
14 function. In addition, the prevalence of SCD-related variants (*LMNA*, *FLNC*, *DSP*, *PLN*, *TMEM43*,  
15 and *RBM20*) was higher in patients with ICD for secondary prevention than in those with ICD for  
16 primary prevention. However, the prevalence was not lower in the non-ICD group (34%) than in the  
17 secondary prevention group, thus suggesting a potential risk of fatal arrhythmia.

18

## 19 **Prevalence and distribution of genetic variants in ICD candidates of DCM**

20 Even after the exclusion of the ischemic and reversible causes of systolic LV dysfunction, the  
21 prevalence of P or LP variants in the core genes was low in patients with sporadic DCM. Although we  
22 further extended the panel to 444 genes, the prevalence of any P/LP variant was not as high as 32%.  
23 However, when we included VUS, the prevalence of the core DCM genes was 56%. Although the role  
24 of the genes included in the extended 444 pan-cardiomyopathy panel was not clear in DCM, almost  
25 all patients (97 %) had VUS. This suggests that a large proportion of patients had genetic mutations in  
26 DCM with persistent LV systolic dysfunction or a history of fatal arrhythmic events. Although the  
27 expert committee recommended limiting the genetic panel size because of the ambiguity of  
28 pathogenicity and concerns about family genetic counseling<sup>9</sup>, the contribution of various genes to the  
29 development or phenotypes of DCM has not been widely investigated compared with hypertrophic  
30 cardiomyopathy. The current study detected not only sarcomere-related mutations but also other  
31 mutations that encode various small organelles. Although the most common mutation was *TTN*, which  
32 is a representative variant of DCM, other gene mutations related to the cytoskeleton, sarcoplasmic

1 reticulum, nuclear envelope, RNA-binding site, desmosome, and ion channels were also detected.<sup>27</sup>  
2 This suggests that multiple pathways are involved in the development of DCM and progression to  
3 advanced HF. Furthermore, this indicates the complexity of gene-based targeted therapy in DCM. In  
4 the current study, the main pathogenic variant was *TTN*, which has been shown to be relatively  
5 benign,<sup>27</sup> and the other important pathogenic gene variant was *DSP*. Although the *DSP* variants are  
6 known to be related to arrhythmogenic right ventricular cardiomyopathy (ARVC),<sup>28</sup> studies have  
7 shown common pathogenicity in ARVC and DCM, thus indicating that they share a genetic  
8 contribution.<sup>3,9</sup> Therefore, in the current study, the interpretation of *DSP* followed the ARVC  
9 pathogenicity criteria. We also identified some roles of *DSP* in the development and progression of  
10 DCM.

11

### 12 **Clinical, echocardiographic, and electrophysiological characteristics according to mutation**

13 In our study, patients with core mutations up to VUS were younger, thus suggesting early disease  
14 onset and early progression to advanced HF. They tended to have lower systolic and diastolic  
15 functions without statistical significance owing to the small population size. This finding is  
16 compatible with that of a recent study by Hofmeyer et al. about the worse prognosis and higher  
17 prevalence of ICD/LVAD/HT in mutation-positive patients.<sup>6</sup> However, in this relatively homogenous  
18 group of patients (97% had LVEF < 35% even after 3 months of GDMT), specific genetic mutations  
19 were not related to LV systolic and diastolic dysfunction, BBB, and AF. In the extended pan-  
20 cardiomyopathy panel, patients with P/LP variants were predominantly female, had a lower rate of  
21 history of hypertension, and were younger but not significantly, thus suggesting a meaningful genetic  
22 contribution. We also grouped the patients according to sarcomere mutation for LV systolic and  
23 diastolic functions and according to the presence of SCD-related genes for electrophysiological  
24 characteristics such as AF, BBB, or number of fragmented QRS in a 12-lead ECG. However, this  
25 failed to reach a statistically significant difference among groups. This suggests that specific  
26 mutations do not contribute to myocardial function or electrophysiological properties. Rather, the  
27 burden of genetic mutations contributes to early disease progression and eventually results in LV  
28 dysfunction and electrophysiological instability.

29

### 30 **SCD genes and real-world practice in ICD candidates of DCM**

31 A recent cardiomyopathy guideline suggested seven SCD gene mutations: *LMNA*, *FLNC* truncating,  
32 *PLN*, *DSP*, *RBM20*, and *TMEM43* mutations.<sup>3</sup> Although gene mutations were not common, *DSP*,

1 *FLNC truncating, RBM20, and TMEM43* VUS were detected in several patients in the current study.  
2 However, in our study, the *LMNA* variant, which is known to be associated with the worst prognosis<sup>29</sup>  
3 was not detected. This might be due to the nature of the relatively low admission of sick patients in  
4 outpatient clinics or general wards. In our study population, the ICD or CRTD implantation rate of the  
5 patients was only 53% even for the Ia or IIa recommendation by current guidelines.<sup>3</sup> It might be due  
6 to the effects of the DANISH trial<sup>4</sup> or recent improvement of GDMT such as sacubitril/valsartan or  
7 sodium-glucose cotransporter-2 inhibitors; therefore, structural and functional reverse remodeling can  
8 be expected after 3 months or patient's denial. We found that the prevalence of SCD gene mutations  
9 tended to be higher in patients with ICD for secondary prevention than in those with ICD for primary  
10 prevention. Interestingly, patients without ICD had a higher prevalence of SCD gene mutations in real  
11 practice in a blinded situation, thus suggesting exposure to the risk of fatal arrhythmias. Regarding  
12 ICD implantation in patients with LVEF < 35%, a genetic test would reinforce to patients and doctors  
13 the need for ICD implantation.

14

#### 15 **Study limitation**

16 First, the study population was relatively homogenous because almost all patients had an LVEF of 35%  
17 or <35% despite the three-month GDMT. Therefore, the differences in phenotypic expression based  
18 on genetic mutations are very narrow. Future long-term follow-up studies are needed to determine the  
19 clinical outcomes. Second, in patients with sporadic DCM, the prevalence of pathogenic mutations is  
20 low; therefore, more patients are needed to identify genetic mutation-related phenotypic differences.

21

#### 22 **Conclusion**

23 In patients with advanced HF and DCM, P/LP-validated DCM variants were not common in sporadic  
24 cases; however, when extended to VUS, more than half of the patients had DCM-related gene variants.  
25 In the advanced HF with DCM group, patients with any related variants had early disease onset. The  
26 prevalence of SCD-related variants tended to be higher in patients with ICDs for secondary  
27 prevention than in those with ICDs for primary prevention. However, the prevalence was not lower in  
28 the non-ICD group (34%), thus suggesting a potential risk of fatal arrhythmia. This suggests that  
29 genetic testing for SCD genes is required before a final decision is made for ICD implantation for  
30 primary prevention.

31

1 **Acknowledgments**

2 None

3 **Sources of Funding**

4 This work was supported by the Basic Science Research Program through the National Research  
5 Foundation of Korea (NRF) funded by the Ministry of Education (2019R1F1A1045911) and Research  
6 Fund of Korean Society of Circulation, (202003-04).

7 **Disclosures**

8 None

## References

1. Schultheiss H-P, Fairweather D, Caforio ALP, Escher F, Hershberger RE, Lipshultz SE, Liu PP, Matsumori A, Mazzanti A, McMurray J, et al. Dilated cardiomyopathy. *Nature Reviews Disease Primers*. 2019;5:32. doi: 10.1038/s41572-019-0084-1
2. McNally EM, Mestroni L. Dilated Cardiomyopathy: Genetic Determinants and Mechanisms. *Circ Res*. 2017;121:731-748. doi: 10.1161/circresaha.116.309396
3. Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, Bezzina CR, Biagini E, Blom NA, de Boer RA, et al. 2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC). *European Heart Journal*. 2023;44:3503-3626. doi: 10.1093/eurheartj/ehad194
4. Køber L, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E, Jensen G, Hildebrandt P, Steffensen FH, Bruun NE, et al. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. *New England Journal of Medicine*. 2016;375:1221-1230. doi: 10.1056/NEJMoa1608029
5. Yafasova A, Butt JH, Elming MB, Nielsen JC, Haarbo J, Videbæk L, Olesen LL, Steffensen FH, Bruun NE, Eiskjær H, et al. Long-Term Follow-Up of DANISH (The Danish Study to Assess the Efficacy of ICDs in Patients With Nonischemic Systolic Heart Failure on Mortality). *Circulation*. 2022;145:427-436. doi: doi:10.1161/CIRCULATIONAHA.121.056072
6. Hofmeyer M, Haas GJ, Jordan E, Cao J, Kransdorf E, Ewald GA, Morris AA, Owens A, Lowes B, Stoller D, et al. Rare Variant Genetics and Dilated Cardiomyopathy Severity: The DCM Precision Medicine Study. *Circulation*. 2023;148:872-881. doi: 10.1161/circulationaha.123.064847
7. Fu Y, Eisen HJ. Genetics of Dilated Cardiomyopathy. *Current Cardiology Reports*. 2018;20:121. doi: 10.1007/s11886-018-1061-0
8. Tayal U, Prasad S, Cook SA. Genetics and genomics of dilated cardiomyopathy and systolic heart failure. *Genome Med*. 2017;9:20. doi: 10.1186/s13073-017-0410-8
9. Jordan E, Peterson L, Ai T, Asatryan B, Bronicki L, Brown E, Celeghein R, Edwards M, Fan J, Ingles J, et al. Evidence-Based Assessment of Genes in Dilated Cardiomyopathy. *Circulation*. 2021;144:7-19. doi: 10.1161/circulationaha.120.053033
10. Chung H, Kim Y, Park CH, Kim JY, Min PK, Yoon YW, Kim TH, Lee BK, Hong BK, Rim SJ, et al. Genetic relevance and determinants of mitral leaflet size in hypertrophic cardiomyopathy. *Cardiovasc Ultrasound*. 2019;17:21. doi: 10.1186/s12947-019-0171-1
11. Walsh R, Thomson KL, Ware JS, Funke BH, Woodley J, McGuire KJ, Mazzarotto F, Blair E, Seller A, Taylor JC, et al. Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples. *Genet Med*. 2017;19:192-203. doi: 10.1038/gim.2016.90

12. Andrews S. FastQC: A quality control tool for high throughput sequence data. In; 2010.
13. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics*. 2014;30:2114-2120. doi: 10.1093/bioinformatics/btu170
14. Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. *arXiv preprint arXiv:13033997*. 2013.
15. Picard Tools. <https://broadinstitute.github.io/picard/>.
16. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, Philippakis AA, del Angel G, Rivas MA, Hanna M, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. *Nat Genet*. 2011;43:491-498. doi: 10.1038/ng.806
17. Koboldt DC, Zhang QY, Larson DE, Shen D, McLellan MD, Lin L, Miller CA, Mardis ER, Ding L, Wilson RK. VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing. *Genome Res*. 2012;22:568-576. doi: 10.1101/gr.129684.111
18. Li H. A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data. *Bioinformatics*. 2011;27:2987-2993. doi: 10.1093/bioinformatics/btr509
19. Plagnol V, Curtis J, Epstein M, Mok KY, Stebbings E, Grigoriadou S, Wood NW, Hambleton S, Burns SO, Thrasher AJ, et al. A robust model for read count data in exome sequencing experiments and implications for copy number variant calling. *Bioinformatics*. 2012;28:2747-2754. doi: 10.1093/bioinformatics/bts526
20. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic acids research*. 2010;38:e164. doi: 10.1093/nar/gkq603
21. Morales A, Kinnamon DD, Jordan E, Platt J, Vatta M, Dorschner MO, Starkey CA, Mead JO, Ai T, Burke W, et al. Variant Interpretation for Dilated Cardiomyopathy: Refinement of the American College of Medical Genetics and Genomics/ClinGen Guidelines for the DCM Precision Medicine Study. *Circulation Genomic and precision medicine*. 2020;13:e002480. doi: 10.1161/circgen.119.002480
22. Richmond CM, James PA, Pantaleo SJ, Chong B, Lunke S, Tan TY, Macciocca I. Clinical and laboratory reporting impact of ACMG-AMP and modified ClinGen variant classification frameworks in MYH7-related cardiomyopathy. *Genet Med*. 2021. doi: 10.1038/s41436-021-01107-y
23. Whiffin N, Minikel E, Walsh R, O'Donnell-Luria AH, Karczewski K, Ing AY, Barton PJR, Funke B, Cook SA, MacArthur D, et al. Using high-resolution variant frequencies to empower clinical genome interpretation. *Genet Med*. 2017;19:1151-1158. doi: 10.1038/gim.2017.26
24. Whiffin N, Walsh R, Govind R, Edwards M, Ahmad M, Zhang X, Tayal U, Buchan R, Midwinter W, Wilk AE, et al. CardioClassifier: disease- and gene-specific computational

- decision support for clinical genome interpretation. *Genet Med.* 2018;20:1246-1254. doi: 10.1038/gim.2017.258
25. Ioannidis NM, Rothstein JH, Pejaver V, Middha S, McDonnell SK, Baheti S, Musolf A, Li Q, Holzinger E, Karyadi D, et al. REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. *Am J Hum Genet.* 2016;99:877-885. doi: 10.1016/j.ajhg.2016.08.016
  26. Pejaver V, Byrne AB, Feng BJ, Pagel KA, Mooney SD, Karchin R, O'Donnell-Luria A, Harrison SM, Tavtigian SV, Greenblatt MS, et al. Calibration of computational tools for missense variant pathogenicity classification and ClinGen recommendations for PP3/BP4 criteria. *Am J Hum Genet.* 2022;109:2163-2177. doi: 10.1016/j.ajhg.2022.10.013
  27. Jordan E, Hershberger RE. Considering complexity in the genetic evaluation of dilated cardiomyopathy. *Heart.* 2021;107:106-112. doi: 10.1136/heartjnl-2020-316658
  28. Protonotarios A, Bariani R, Cappelletto C, Pavlou M, García-García A, Cipriani A, Protonotarios I, Rivas A, Wittenberg R, Graziosi M, et al. Importance of genotype for risk stratification in arrhythmogenic right ventricular cardiomyopathy using the 2019 ARVC risk calculator. *Eur Heart J.* 2022;43:3053-3067. doi: 10.1093/eurheartj/ehac235
  29. van Rijsingen IA, Arbustini E, Elliott PM, Mogensen J, Hermans-van Ast JF, van der Kooi AJ, van Tintelen JP, van den Berg MP, Pilotto A, Pasotti M, et al. Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European cohort study. *J Am Coll Cardiol.* 2012;59:493-500. doi: 10.1016/j.jacc.2011.08.078

**Table 1.** Comparisons between the P/LP variant group and others regarding the 36 core DCM genes

	<b>Total (n=105)</b>	<b>No P/LP variants (n=91)</b>	<b>Presence of P/LP variants in Core genes (n=14)</b>	<b>p</b>
<b>Age, yrs</b>	65.0 (57.5 -75.0)	66 (58 -76)	63.5 (53-67)	0.367
<b>Female, n (%)</b>	33 (31)	27 (30)	6 (43)	0.468
<b>Diabetes, n (%)</b>	36 (34)	30 (33)	6 (43)	0.555
<b>Hypertension, n (%)</b>	67 (64)	56 (62)	11 (79)	0.217
<b>Smoking status, quit/current n (%)</b>	27/14 (39)	25/12 (41)	2/2 (29)	0.571
<b>Hb, g/dL</b>	13.5±2.1	13.6±2.1	13.4±2.1	0.626
<b>Na, mEq/mL</b>	139 (137-141)	139 (137-141)	139.5 (138-141.3)	0.464
<b>eGFR, mL/min/1.73m<sup>2</sup></b>	75 (53-91)	73 (51.3-92.5)	75 (53-89)	0.922
<b>AF, n (%)</b>	29 (28)	26 (29)	3 (21)	0.578
<b>LBBB/RBBB, n (%)</b>	24 / 4 (27)	23/4 (30)	1/0 (7)	0.202
<b>QRS duration, ms</b>	106 (97-141)	110 (98-144)	101 (91-112)	0.637
<b>No of fQRS, n</b>	2 (0-5)	2 (0-6)	2 (0-3.3)	0.676
<b>ICD/CRTD, n (%)</b>	33 / 13 (44)	26 / 13 (43)	7 / 0 (50)	0.143
<b>ICD for 2<sup>nd</sup> prevention</b>	12 (11)	10 (11)	2 (14)	0.869
<b>LVEF, %</b>	27.4±5.9	27.5±6.2	27.3±5.1	0.869
<b>LVEDD, mm</b>	61.4±7.9	61.3±8.2	61.5±7.1	0.890
<b>LV mass index, g/m<sup>2</sup></b>	139.8±39.7	138.2±42.1	144.0±36.4	0.524
<b>s<sup>2</sup>, cm/s</b>	4 (3-5)	4 (3-5)	3.5 (2.8-4.2)	0.559
<b>E, cm/s</b>	71.0 (52.5-97.8)	71 (54-96.3)	57.5 (34.4-96.3)	0.257
<b>e<sup>2</sup>, cm/s</b>	5 (4-6)	5 (4-6)	4 (2.9-5)	0.823
<b>E/e'</b>	14.0 (10.8-19.2)	13.5 (10.4-19.0)	15.9 (10.8-21.0)	0.050
<b>Functional MR, n</b>	2 (1-2)	2 (1-2)	2 (1-2)	0.994
<b>LA dimension, mm</b>	45.0±8.4	45.6±7.6	44.5±9.0	0.606
<b>LAVI, mL/m<sup>2</sup></b>	48.1 (34.7-61.2)	48.0 (35.0-59.1)	49.5 (27.9-67.8)	0.660
<b>TRV max, m/s</b>	2.3 (2.1-2.7)	2.3 (2.1-2.6)	2.3 (2.1-2.8)	0.607
<b>ARNI, n (%)</b>	80 (76)	68 (75)	12 (86)	0.369
<b>ARB/ACEi, n (%)</b>	24 (23)	23 (25)	1(7)	0.133
<b>Beta blockers, n (%)</b>	91 (87)	78 (86)	13 (93)	0.464



<b>MRA, n (%)</b>	58 (55)	51 (56)	7 (50)	0.672
-------------------	---------	---------	--------	-------

eGFR, estimated glomerular filtration rate; LBBB, left bundle branch block; RBBB, right bundle branch block; fQRS, fragmented QRS; ICD, implantable cardioverter–defibrillator; CRTD, cardiac resynchronization therapy with defibrillator; LA, left atrial; LAVI, LA volume index; TRV, tricuspid regurgitant velocity; ARB, angiotensin II receptor blocker; ARNI, angiotensin II receptor and neprilysin inhibitor; MRA, mineralocorticoid receptor antagonist; functional MR, functional mitral regurgitation (0 = none, 1 = trivial, 2 = mild, 3 = moderate, 4 = severe).

**Table 2.** Comparison between the 36 core DCM variants group and the no variants group up to VUS

	<b>No core variants</b> (n = 46)	<b>36 core DCM variants</b> (n = 59)	<b>p</b>
<b>Age, yrs</b>	68 (58.0 -78.0)	64.5 (56.3-74.3)	0.391
<b>Female, n (%)</b>	14 (30)	19 (32)	0.846
<b>Diabetes, n (%)</b>	17 (37)	19 (32)	0.611
<b>Hypertension, n (%)</b>	27 (59)	40 (68)	0.244
<b>Smoking status</b> quit/current, (%)	10/4 (30)	17/10 (46)	0.306
<b>Hb, g/dL</b>	13.5±2.3	13.5±1.9	0.968
<b>Na, mEq/mL</b>	139 (136-141)	139 (137-141)	0.730
<b>eGFR, mL/min/1.73m<sup>2</sup></b>	71.1 (49.1-92.6)	79.6 (55.4-90.6)	0.504
<b>AF, n (%)</b>	15 (33)	14 (24)	0.313
<b>LBBB/RBBB, n (%)</b>	11 / 3 (30)	13/1 (24)	0.411
<b>QRS duration, ms</b>	106 (92-150)	110 (100-134)	0.660
<b>No of fQRS, n</b>	1 (0-5.3)	2 (0-5)	0.449
<b>ICD/CRTD, n (%)</b>	14 / 8 (48)	19 / 5 (40)	0.383
<b>ICD for 2<sup>nd</sup> prevention</b>	5 (11)	7 (12)	0.675
<b>LVEF, %</b>	28.3±6.7	26.7±5.2	0.170
<b>LVEDD, mm</b>	61.6±8.7	61.2±7.3	0.828
<b>LV mass index, g/m<sup>2</sup></b>	140.4±44.0	139.2±38.0	0.878
<b>s<sup>2</sup>, cm/s</b>	4 (3-5)	4 (3-5)	0.777
<b>E, cm/s</b>	69 (50.5-84.8)	69 (51.8-99.3)	0.675
<b>e<sup>2</sup>, cm/s</b>	6 (4-6.8)	5 (4-6)	0.121
<b>E/e'</b>	12.8 (9.8-18.5)	14.0 (11.2-20.5)	0.157
<b>Functional MR, n</b>	2 (1-2.3)	2 (1-2)	0.581
<b>LA dimension, mm</b>	45.4±7.5	44.6±9.1	0.647
<b>LAVI, mL/m<sup>2</sup></b>	51.2 (35.0-59.1)	46.5 (33.6-63.8)	0.718
<b>TRV max, m/s</b>	2.3 (2.2-2.7)	2.3 (2.0-2.7)	0.711
<b>ARNI, n (%)</b>	32 (70)	48 (81)	0.159
<b>ARB/ACEi, n (%)</b>	12 (26)	12 (20)	0.486
<b>Beta blockers, n (%)</b>	37 (80)	54 (92)	0.097

<b>MRA, n (%)</b>	25 (54)	33 (56)	0.871
-------------------	---------	---------	-------

See abbreviations in table 1.

**Table 3.** Comparison between P/LP variants and others in the 444 pan-cardiomyopathy gene panel

	<b>No P/LP variants (n=71)</b>	<b>Presence of P/LP variants (n=34)</b>	<b>p</b>
<b>Age, yrs</b>	67 (59 -76)	63.5 (53-71.3)	0.367
<b>Female, n (%)</b>	17 (24)	16 (47)	0.017
<b>Diabetes, n (%)</b>	23 (32)	13 (38)	0.555
<b>Hypertension, n (%)</b>	30 (42)	8 (24)	0.062
<b>Smoking status,</b>	24/8 (45)	3/6 (27)	0.023
<b>Hb, g/dL</b>	13.6±2.1	13.4±2.1	0.626
<b>Na, mEq/mL</b>	139 (137-141)	139 (138-140)	0.464
<b>eGFR,mL/min/1.73m<sup>2</sup></b>	76.5 (53.1-91.8)	75 (53-89)	0.922
<b>AF, n (%)</b>	21 (30)	8 (24)	0.517
<b>LBBB/RBBB, n (%)</b>	17/2 (27)	7/2 (27)	0.712
<b>QRS duration, ms</b>	110 (96-144)	105 (93.5-139)	0.637
<b>No of fQRS, n</b>	2 (0-6)	2 (0-4)	0.676
<b>ICD/CRTD, n (%)</b>	21 / 11 (45)	12 / 2 (40)	0.365
<b>ICD for 2<sup>nd</sup> prevention</b>	6 (9)	6 (18)	0.225
<b>LVEF, %</b>	27.5±6.2	27.3±5.1	0.869
<b>LVEDD, mm</b>	61.3±8.2	61.5±7.1	0.890
<b>LV mass index, g/m<sup>2</sup></b>	138.2±42.1	144.0±36.4	0.524
<b>s<sup>2</sup>, cm/s</b>	4 (3-5)	4 (4-5)	0.559
<b>E, cm/s</b>	67 (49-87)	71 (56-110)	0.257
<b>e<sup>2</sup>, cm/s</b>	5 (4-6)	5 (4-6)	0.823
<b>E/e'</b>	13.1 (10.0-17.5)	16.2 (13.1-21.7)	0.050
<b>Functional MR, n</b>	2 (1-2)	2 (1-2)	0.994
<b>LA dimension, mm</b>	45.6±7.6	44.5±9.0	0.606
<b>LAVI, mL/m<sup>2</sup></b>	48.1 (34.2-59.3)	48.6 (37.7-64.9)	0.660
<b>TRV max, m/s</b>	2.3 (2.1-2.6)	2.4 (2.1-2.8)	0.607
<b>ARNI, n (%)</b>	52 (73)	28 (82)	0.305
<b>ARB/ACEi, n (%)</b>	19 (27)	5 (15)	0.169
<b>Beta blockers, n (%)</b>	64 (90)	27 (79)	0.130

<b>MRA, n (%)</b>	40 (56)	18 (53)	0.743
-------------------	---------	---------	-------

See abbreviations in table 1.

**Table 4.** Comparisons between sarcomere-related gene mutation and others for clinical characteristics

	<b>Other variants (n=29)</b>	<b>Sarcomere variants (n=29)</b>	<b>No mutation (n=47)</b>	<b>p</b>
<b>Age, yrs</b>	66 (60.5 -74)	62 (53.5 -74.5)	68 (58-78)	0.537
<b>Female, n (%)</b>	9 (31)	10 (35)	14 (30)	0.911
<b>Diabetes, n (%)</b>	7 (24)	11(38)	29 (38)	0.400
<b>Hypertension, n (%)</b>	20 (69)	19 (66)	28 (60)	0.692
<b>Smoking status</b>	10/4 (48)	6/6 (41)	11/4 (32)	0.396
<b>Hb, g/dL</b>	13.4±2.0	13.7±1.7	13.5±2.3	0.913
<b>Na, mEq/mL</b>	139 (137-140)	140 (138-141.5)	139 (135.5-141)	0.263
<b>eGFR,mL/min/1.73m<sup>2</sup></b>	72.5 (48.3-88.8)	84 (70.8-92)	71.1 (48.1-92.3)	0.147
<b>AF, n (%)</b>	7 (24)	6 (21)	16 (34)	0.398
<b>LBBB/RBBB, n (%)</b>	8 / 1 (31)	5 / 0 (18)	11/3 (30)	0.539
<b>QRS duration, ms</b>	116 (99-147)	106 (98-123)	106 (92-150)	0.500
<b>No of rQRS, n</b>	3 (0-6)	2 (0-3.5)	1 (0-6)	0.839
<b>ICD/CRTD, n (%)</b>	8/2 (35)	10/3 (45)	15/8 (49)	0.641
<b>ICD for 2<sup>nd</sup> prevention</b>	4 (14)	3(10)	5 (11)	0.619
<b>LVEF, %</b>	27.1±4.9	26.7±5.4	28.1±6.8	0.556
<b>LVEDD, mm</b>	62.2±6.8	59.9±7.6	61.7±8.7	0.317
<b>LV mass index, g/m<sup>2</sup></b>	148.2±37.8	130.3±37.5	140.4±43.5	0.242
<b>s<sup>2</sup>, cm/s</b>	4 (3-5)	4 (3-5)	6 (4-6.8)	0.786
<b>E, cm/s</b>	78.0 (57.5-101.8)	57 (40.5-98.5)	67 (49.5-84.5)	0.119
<b>e<sup>2</sup>, cm/s</b>	5 (4-6)	5 (3.9-6.1)	6 (4-6.8)	0.441
<b>E/e'</b>	16.0 (13.4-21.4)	12.9 (10-17.2)	12.8 (9.8-18.5)	0.019
<b>Functional MR, n</b>	2 (1-2)	2 (1-2)	2 (1-3)	0.678
<b>LA dimension, mm</b>	45.9±8.8	43.1±9.2	45.6±7.6	0.352
<b>LAVI, mL/m<sup>2</sup></b>	50.0 (39.5-66.7)	41.0 (29.8-58.3)	51.2 (35.0-59.1)	0.134
<b>TRV max, m/s</b>	2.4 (2.1-2.8)	2.2 (2.0-2.4)	2.3 (2.2-2.7)	0.285
<b>ARNI, n (%)</b>	22 (76)	25 (86)	33 (70)	0.282
<b>ARB/ACEi, n (%)</b>	9 (31)	3 (10)	12 (25)	0.145
<b>Beta blockers, n (%)</b>	26 (90)	27 (93)	38 (81)	0.267

<b>MRA, n (%)</b>	19 (66)	14 (48)	25 (53)	0.389
-------------------	---------	---------	---------	-------

See abbreviations in table 1.

**Table 5.** Comparison between patients with SCD gene variants and others

	<b>No SCD gene variants (n=77)</b>	<b>SCD gene variants (n=28)</b>	<b>p</b>
<b>Age, yrs</b>	64 (57 -75.5)	65.5 (61-75)	0.897
<b>Female, n (%)</b>	21 (27)	12 (43)	0.128
<b>Diabetes, n (%)</b>	18 (23)	9 (32)	0.457
<b>Hypertension, n (%)</b>	49 (64)	18 (64)	0.951
<b>Smoking status,</b>	18/12 (39)	9/2 (39)	0.425
<b>Hb, g/dL</b>	13.6±2.1	13.4±2.1	0.626
<b>Na, mEq/mL</b>	139 (137-141)	139 (138-140)	0.464
<b>eGFR,mL/min/1.73m<sup>2</sup></b>	76.5 (53.1-91.8)	75 (53-89)	0.922
<b>AF, n (%)</b>	23 (30)	6 (21)	0.392
<b>LBBB/RBBB, n (%)</b>	18/3 (27)	6/2 (24)	0.449
<b>QRS duration, ms</b>	110 (96-144)	105 (93.5-139)	0.637
<b>No of fQRS, n</b>	2 (0-6)	2 (0-4)	0.676
<b>ICD/CRTD, n (%)</b>	27 / 11 (49)	6 / 2 (29)	0.162
<b>ICD for 2<sup>nd</sup> prevention</b>	8 (10)	4 (14)	0.058
<b>LVEF, %</b>	27.5±6.2	27.3±5.1	0.869
<b>LVEDD, mm</b>	61.3±8.2	61.5±7.1	0.890
<b>LV mass index, g/m<sup>2</sup></b>	138.2±42.1	144.0±36.4	0.524
<b>s<sup>2</sup>, cm/s</b>	4 (3-5)	4 (4-5)	0.559
<b>E, cm/s</b>	67 (49-87)	71 (56-110)	0.257
<b>e<sup>2</sup>, cm/s</b>	5 (4-6)	5 (4-6)	0.823
<b>E/e'</b>	13.1 (10.0-17.5)	16.2 (13.1-21.7)	0.050
<b>Functional MR, n</b>	2 (1-2)	2 (1-2)	0.994
<b>LA dimension, mm</b>	45.6±7.6	44.5±9.0	0.606
<b>LAVI, mL/m<sup>2</sup></b>	48.1 (34.2-59.3)	48.6 (37.7-64.9)	0.660
<b>TRV max, m/s</b>	2.3 (2.1-2.6)	2.4 (2.1-2.8)	0.607
<b>ARNI, n (%)</b>	58 (75)	22 (79)	0.195
<b>ARB/ACEi, n (%)</b>	16 (21)	8 (29)	0.400
<b>Beta blockers, n (%)</b>	66 (86)	25 (89)	0.634

MRA, n (%)	40 (52)	18 (64)	0.261
------------	---------	---------	-------

See abbreviations in Table 1.

## Figure legends

**Figure 1.** Gene panel for 36 core dilated cardiomyopathy (DCM) variants


<i>ABCC9</i>	<i>EYA4</i>	<i>MYPN</i>	<i>TNNC1</i> ●
<i>ACTC1</i> ■	<i>FLNC</i> * ●	<i>NEBL</i>	<i>TNNI3</i> ■
<i>ACTN2</i> ■	<i>ILK</i>	<i>NEXN</i> ■	<i>TNNT2</i> ●
<i>ANKRD1</i>	<i>LAMA4</i>	<i>PDLIM3</i>	<i>TPM1</i> ■
<i>BAG3</i> * ●	<i>LDB3</i>	<i>PKP2</i>	<i>TTN</i> * ●
<i>CRYAB</i>	<i>JPH2</i> ■	<i>PLN</i> * ●	<i>VCL</i> ■
<i>CSRP3</i>	<i>LMNA</i> * ●	<i>RBM20</i> ●	
<i>DES</i> ●	<i>MYBPC3</i>	<i>SCN5A</i> * ●	
<i>DSG2</i>	<i>MYH6</i>	<i>SGCD</i>	
<i>DSP</i> * ●	<i>MYH7</i> ●	<i>TCAP</i>	

Sarcomere associated genes


- Sarcomere
- Z-disc
- Cytoskeleton
- Co-chaperone, heat shock protein
- Sarcoplasmic reticulum
- Nuclear envelope
- RNA binding
- Transcription factor
- Desmosome
- Ion channel
- Junctional membrane

Genes with high evidence [12 definitive/strong (●) and 7 moderate (■)] according to DCM Gene Curation Expert Panel according to ClinGen.<sup>9</sup> Those with loss of function as an established DCM-causing mechanism<sup>27</sup> are noted with an asterisk (\*).

**Figure 2.** Distribution and prevalence of P/LP/VUS in the 36 core DCM-associated genes



**Figure 3.** Prevalence of sudden cardiac death (SCD) gene variants according to implantable cardioverter defibrillator (ICD) implantation





## Supplemental Figure

AARS2	ALPK3	BRIP1	COA8	DCAF8	ERCC3	FKRP	GNPTAB	HGSNAT	KAT6B	LRRC10	MRPS22	NDUFA10	NDUF54	OPA1	PEX5	PPCS	RNASEH2	SHOC2	STAR	TMEM126	TSM	XYLT1
ABCC6	ANK1	B5CL2	COG7	DES	ERCC4	FKTN	GNS	HJV	K8TBD13	LTBP4	MTFMT	NDUFA11	NDUF56	PALB2	PEX6	PPP1CB	RNF113A	SKI	SUFU	TMEM126	TTN	XYLT2
ABCC9	ANKRD1	C1QB	COL7A1	DLD	EYA4	FLAD1	GPC3	HLA-B	KCNH1	MAD2L2	MTO1	NDUFA12	NDUF57	PARS2	PEX7	PRDM16	RRM2B	SLC19A2	SURF1	TMEM43	TTPA	YARS2
ABHD5	ANKRD11	CACNA1C	COQ2	DMD	FAH	FLNC	GPC4	HMGCL	KCNQ1	MAP2K1	MYBPC3	NDUFA13	NDUF58	PCCA	PGM1	PRKAG2	RYR1	SLC19A3	SYNE1	TMEM70	TTR	ZBTB17
ACAD8	ANKS6	CALR3	COQ4	DNAJC19	FANCA	FOXD4	GPR101	HNRNP1A1	KLF1	MAP2K2	MYH6	NDUFA2	NDUFV1	PCCB	PHYH	PSEN1	RYR2	SLC22A5	SYNE2	TMPO	TWNK	
ACAD9	ANOS	CASQ2	COQ9	DOLK	FANCB	FOXRED1	GSN	HNRNP2A2	KLF10	MAP3K20	MYH7	NDUFA6	NDUFV2	PDGFRA	PIGT	PSEN2	SAMHD1	SLC25A20	SYNM	TNNC1	TXNRD2	
ACADS	ARS8	CAV1	COX10	DPM3	FANCC	FTO	GTFE22	HOPX	KLHL41	MC2R	MYL2	NDUFA9	NEB	PDHA1	PKP2	PTPN11	SARDH	SLC25A3	TACO1	TNNI3	UBE2T	
ACADVL	ATAD3A	CAV3	COX14	DSC2	FANCD2	FXN	GTFE2H5	HPS1	KRAS	MGME1	MYL3	NDUFAF1	NEBL	PDLM3	PLEC	RAB3GAP	SCN5A	SLC25A4	TANGO2	TNNI3K	UBR1	
ACTA1	ATP5F1D	CAVIN1	COX15	DSG2	FANCE	GAA	GPBP3	HRA5	LAMA2	MIB1	MYLK2	NDUFAF2	NEK8	PET100	PLEKHM2	RAD51	SCO1	SLC2A10	TAPT1	TNNT2	USP8	
ACTC1	ATP5F1E	CAVIN4	COX20	DSP	FANCF	GABRD	GUSB	HSD17B10	LAMA3	MICOS13	MYO18B	NDUFAF3	NEU1	PEX1	PLN	RAD51C	SCO2	SLC30A10	TAZ	TOP3A	USP9X	
ACTN2	ATP6V1A	CDH23	COX6B1	DTNA	FANCG	GATA4	GYG1	IDH2	LAMA4	MICU1	MYO6	NDUFAF4	NEXN	PEX10	PMM2	RAF1	SDHA	SLC40A1	TBX20	TPI1	VAC14	
ADAR	ATPAF2	CDKN1C	COX7B	ECHS1	FANCI	GATA5	GSY1	IDUA	LAMB3	MIEP	MYOM1	NDUFAF5	NF1	PEX11B	PNPLA2	RBCK1	SDHAF1	SLC4A1	TBX5	TPM1	VCL	
ADCY5	BAG3	CENPE	COX8A	ELAC2	FANCL	GATAD1	HADH	IFIH1	LAMC2	MLYCD	MYOT	NDUFAF6	NFKB1	PEX12	POLG	RBM20	SDHB	SLX4	TCAP	TPM2	VCP	
AGK	BBS2	CHK8	CPT1A	ELN	FANCM	GBE1	HADHA	IGF2	LAMP2	MMP1	MYOZ2	NDUF811	NKX2-5	PEX13	POLG2	RERE	SDHD	SMC1A	TERT	TPM3	VP513A	
AGL	BCL2L1	CHRM2	CPT2	EMD	FASTKD2	GJA5	HADHB	IL12B	LD33	MMUT	MYPN	NDUF83	NNT	PEX14	POMGNT	RFWD3	SELENON	SOD2	TFR2	TRDN	VP533A	
AGPAT2	BMP2	CISD2	CRYAB	ENPP1	FBXL4	GLA	HAMP	ILK	LIAS	MPLKIP	NAGA	NDUF88	NPPA	PEX16	POMK	RIT1	SGCA	SOS1	TGFB1	TREX1	WARS2	
AHCY	BOLA3	CLN3	CSR3	EPB42	FHL1	GLB1	HRB	ITGA7	LIMS2	MRAP	NAGLU	NDUF89	NRAS	PEX19	POMT1	RMND1	SGCB	SPEG	TGFB3	TRIM54	WFS1	
AIP	BRAF	CLPB	CTF1	EPG5	FHL2	GMPPB	HCC5	ITPA	LPT1	MRPL3	NAXD	NDUF51	NUBPL	PEX2	POMT2	RNASEH1	SGCD	SPTA1	TIA1	TRIP4	XK	
ALG1	BRCA1	COA5	CTNNA3	ERBB3	FHOD3	GNAI2	HGN4	JPH2	LMNA	MRPL44	NBAS	NDUF52	NUP107	PEX26	PPA2	RNASEH2	SGCG	SPTB	TIMMDC1	TRMT5	XRCC2	
ALMS1	BRCA2	COA6	D2HGDH	ERCC2	FIG4	GNE	HFE	JUP	LRRPRC	MRPS14	NDUFA1	NDUF53	OBSCN	PEX3	PPARG	RNASEH2	SGSH	SRI	TK2	TRNT1	XRCC4	

The 444 pan-cardiomyopathy gene panel. Yellow box indicates 36 core DCM associated genes.